nach oben

Erschienen in:

27.01.2021 | Main topic

Neglected cardiovascular diseases and their significance in the Global North

verfasst von: Charle André Viljoen, Julian Hoevelmann, Elani Muller, Prof. Karen Sliwa

Erschienen in: Herz | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Due to increasing global migration, the spectrum of cardiovascular disease (CVD) is changing in developed countries. Up to 3% of migrants arriving in Europe have underlying CVD. Despite their high global prevalence, conditions such as rheumatic heart disease, Chagas disease, endomyocardial fibrosis, tuberculous pericarditis, peripartum cardiomyopathy, and pulmonary hypertension are often under-recognized, and, as a result, neglected in industrialized countries. Many of these conditions, and their causes, are often unfamiliar to the health-care providers in host countries. In this review, we summarize the epidemiology, etiology, clinical presentation, diagnostic work-up, and management of neglected CVDs that have an increasing prevalence in the Global North.

Smith SC Jr., Collins A, Ferrari R et al (2012) Our time: a call to save preventable death from cardiovascular disease (heart disease and stroke). Circulation 126(23):2769–2775. https://doi.org/10.1161/CIR.0b013e318267e99fCrossRefPubMed

Roth GA, Huffman MD, Moran AE et al (2015) Global and regional patterns in cardiovascular mortality from 1990 to 2013. Circulation 132(17):1667–1678. https://doi.org/10.1161/circulationaha.114.008720CrossRefPubMed

Odone A, McKee C, McKee M (2018) The impact of migration on cardiovascular diseases. Int J Cardiol 254:356–361. https://doi.org/10.1016/j.ijcard.2017.11.084CrossRefPubMed

Pavli A, Maltezou H (2017) Health problems of newly arrived migrants and refugees in Europe. J Travel Med. https://doi.org/10.1093/jtm/tax016CrossRefPubMed

Watkins DA, Johnson CO, Colquhoun SM et al (2017) Global, regional, and national burden of rheumatic heart disease, 1990–2015. N Engl J Med 377(8):713–722. https://doi.org/10.1056/NEJMoa1603693CrossRefPubMed

Zühlke L, Engel ME, Karthikeyan G et al (2015) Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the global rheumatic heart disease registry (the REMEDY study). Eur Heart J 36(18):1115–1122a. https://doi.org/10.1093/eurheartj/ehu449CrossRefPubMed

Gewitz MH, Baltimore RS, Tani LY et al (2015) Revision of the Jones criteria for the diagnosis of acute rheumatic fever in the era of doppler echocardiography: a scientific statement from the American heart association. Circulation 131(20):1806–1818. https://doi.org/10.1161/cir.0000000000000205CrossRefPubMed

Watkins DA, Beaton AZ, Carapetis JR et al (2018) Rheumatic heart disease worldwide: JACC scientific expert panel. J Am Coll Cardiol 72(12):1397–1416. https://doi.org/10.1016/j.jacc.2018.06.063CrossRefPubMed

Marijon E, Mirabel M, Celermajer DS, Jouven X (2012) Rheumatic heart disease. Lancet 379(9819):953–964. https://doi.org/10.1016/s0140-6736(11)61171-9CrossRefPubMed

10.

Peters F, Karthikeyan G, Abrams J et al (2020) Rheumatic heart disease: current status of diagnosis and therapy. Cardiovasc Diagn Ther 10(2):305–315. https://doi.org/10.21037/cdt.2019.10.07CrossRefPubMedPubMedCentral

11.

Zühlke L, Karthikeyan G, Engel ME et al (2016) Clinical outcomes in 3343 children and adults with rheumatic heart disease from 14 low- and middle-income countries: two-year follow-up of the global rheumatic heart disease registry (the REMEDY study). Circulation 134(19):1456–1466. https://doi.org/10.1161/circulationaha.116.024769CrossRefPubMed

12.

Carapetis JR, Beaton A, Cunningham MW et al (2016) Acute rheumatic fever and rheumatic heart disease. Nat Rev Dis Primers 2:15084. https://doi.org/10.1038/nrdp.2015.84CrossRefPubMedPubMedCentral

13.

Reményi B, Wilson N, Steer A et al (2012) World heart federation criteria for echocardiographic diagnosis of rheumatic heart disease—an evidence-based guideline. Nat Rev Cardiol 9(5):297–309. https://doi.org/10.1038/nrcardio.2012.7CrossRefPubMedPubMedCentral

14.

Bern C (2015) Chagas’ disease. N Engl J Med 373(5):456–466. https://doi.org/10.1056/NEJMra1410150CrossRefPubMed

15.

Manne-Goehler J, Umeh CA, Montgomery SP, Wirtz VJ (2016) Estimating the burden of Chagas disease in the United States. PLoS Negl Trop Dis 10(11):e5033. https://doi.org/10.1371/journal.pntd.0005033CrossRefPubMedPubMedCentral

16.

Rassi A Jr., Rassi A, Marin-Neto JA (2010) Chagas disease. Lancet 375(9723):1388–1402. https://doi.org/10.1016/S0140-6736(10)60061-XCrossRefPubMed

17.

Nunes MCP, Beaton A, Acquatella H et al (2018) Chagas cardiomyopathy: an update of current clinical knowledge and management: a scientific statement from the American heart association. Circulation 138(12):e169–e209. https://doi.org/10.1161/cir.0000000000000599CrossRefPubMed

18.

Ribeiro AL, Marcolino MS, Prineas RJ, Lima-Costa MF (2014) Electrocardiographic abnormalities in elderly Chagas disease patients: 10-year follow-up of the Bambui cohort study of aging. J Am Heart Assoc 3(1):e632. https://doi.org/10.1161/jaha.113.000632CrossRefPubMedPubMedCentral

19.

Acquatella H (2007) Echocardiography in Chagas heart disease. Circulation 115(9):1124–1131. https://doi.org/10.1161/circulationaha.106.627323CrossRefPubMed

20.

Regueiro A, García-Álvarez A, Sitges M et al (2013) Myocardial involvement in Chagas disease: insights from cardiac magnetic resonance. Int J Cardiol 165(1):107–112. https://doi.org/10.1016/j.ijcard.2011.07.089CrossRefPubMed

21.

Bern C, Montgomery SP, Herwaldt BL et al (2007) Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA 298(18):2171–2181. https://doi.org/10.1001/jama.298.18.2171CrossRefPubMed

22.

Mocumbi AO (2012) Endomyocardial fibrosis: a form of endemic restrictive cardiomyopathy. Glob Cardiol Sci Pract 2012(1):11. https://doi.org/10.5339/gcsp.2012.11CrossRefPubMedPubMedCentral

23.

Grimaldi A, Mocumbi AO, Freers J et al (2016) Tropical endomyocardial fibrosis: natural history, challenges, and perspectives. Circulation 133(24):2503–2515. https://doi.org/10.1161/CIRCULATIONAHA.115.021178CrossRefPubMed

24.

Mocumbi AO, Stothard JR, Correia-de-Sá P, Yacoub M (2019) Endomyocardial fibrosis: an update after 70 years. Curr Cardiol Rep 21(11):148. https://doi.org/10.1007/s11886-019-1244-3CrossRefPubMed

25.

Mocumbi AO, Ferreira MB, Sidi D, Yacoub MH (2008) A population study of endomyocardial fibrosis in a rural area of Mozambique. N Engl J Med 359(1):43–49. https://doi.org/10.1056/NEJMoa0708629CrossRefPubMed

26.

Beaton A, Mocumbi AO (2017) Diagnosis and management of endomyocardial fibrosis. Cardiol Clin 35(1):87–98. https://doi.org/10.1016/j.ccl.2016.08.005CrossRefPubMed

27.

Mocumbi AO, Falase AO (2013) Recent advances in the epidemiology, diagnosis and treatment of endomyocardial fibrosis in Africa. Heart 99(20):1481–1487. https://doi.org/10.1136/heartjnl-2012-303193CrossRefPubMed

28.

Murray JF (2004) A century of tuberculosis. Am J Respir Crit Care Med 169(11):1181–1186. https://doi.org/10.1164/rccm.200402-140OECrossRefPubMed

29.

Mayosi BM, Burgess LJ, Doubell AF (2005) Tuberculous pericarditis. Circulation 112(23):3608–3616. https://doi.org/10.1161/circulationaha.105.543066CrossRefPubMed

30.

Naicker K, Ntsekhe M (2020) Tuberculous pericardial disease: a focused update on diagnosis, therapy and prevention of complications. Cardiovasc Diagn Ther 10(2):289–295. https://doi.org/10.21037/cdt.2019.09.20CrossRefPubMedPubMedCentral

31.

Ntsekhe M, Mayosi BM (2013) Tuberculous pericarditis with and without HIV. Heart Fail Rev 18(3):367–373. https://doi.org/10.1007/s10741-012-9310-6CrossRefPubMed

32.

Mutyaba AK, Ntsekhe M (2017) Tuberculosis and the heart. Cardiol Clin 35(1):135–144. https://doi.org/10.1016/j.ccl.2016.08.007CrossRefPubMed

33.

Smedema JP, Katjitae I, Reuter H et al (2001) Twelve-lead electrocardiography in tuberculous pericarditis. Cardiovasc J S Afr 12(1):31–34PubMed

34.

Isiguzo G, Du Bruyn E, Howlett P, Ntsekhe M (2020) Diagnosis and management of tuberculous pericarditis: what is new? Curr Cardiol Rep 22(1):2. https://doi.org/10.1007/s11886-020-1254-1CrossRefPubMedPubMedCentral

35.

Yew WW, Lange C, Leung CC (2011) Treatment of tuberculosis: update 2010. Eur Respir J 37(2):441–462. https://doi.org/10.1183/09031936.00033010CrossRefPubMed

36.

Mayosi BM, Ntsekhe M, Bosch J et al (2014) Prednisolone and mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med 371(12):1121–1130. https://doi.org/10.1056/NEJMoa1407380CrossRefPubMedPubMedCentral

37.

Mutyaba AK, Balkaran S, Cloete R et al (2014) Constrictive pericarditis requiring pericardiectomy at Groote Schuur hospital, cape town, south africa: causes and perioperative outcomes in the HIV era (1990–2012). J Thorac Cardiovasc Surg 148(6):3058–3065.e1. https://doi.org/10.1016/j.jtcvs.2014.07.065CrossRefPubMed

38.

Bauersachs J, Konig T, van der Meer P et al (2019) Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the heart failure association of the European society of cardiology study group on peripartum cardiomyopathy. Eur J Heart Fail 21(7):827–843. https://doi.org/10.1002/ejhf.1493CrossRefPubMed

39.

Douglass EJ, Blauwet LA (2021) Peripartum cardiomyopathy. Cardiol Clin 39(1):119–142. https://doi.org/10.1016/j.ccl.2020.09.008CrossRefPubMed

40.

Sliwa K, Petrie MC, van der Meer P et al (2020) Clinical presentation, management, and 6‑month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. Eur Heart J 41(39):3787–3797. https://doi.org/10.1093/eurheartj/ehaa455CrossRefPubMedPubMedCentral

41.

Hoevelmann J, Hahnle L, Hahnle J et al (2020) Detection and management of arrhythmias in peripartum cardiomyopathy. Cardiovasc Diagn Ther 10(2):325–335. https://doi.org/10.21037/cdt.2019.05.03CrossRefPubMedPubMedCentral

42.

Arrigo M, Blet A, Mebazaa A (2017) Bromocriptine for the treatment of peripartum cardiomyopathy: welcome on BOARD. Eur Heart J 38(35):2680–2682. https://doi.org/10.1093/eurheartj/ehx428CrossRefPubMed

43.

Hilfiker-Kleiner D, Haghikia A, Berliner D et al (2017) Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Eur Heart J 38(35):2671–2679. https://doi.org/10.1093/eurheartj/ehx355CrossRefPubMedPubMedCentral

44.

Sliwa K, Petrie MC, van der Meer P et al (2020) Clinical presentation, management, and 6‑month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. Eur Heart J. https://doi.org/10.1093/eurheartj/ehaa455CrossRefPubMedPubMedCentral

45.

Pfeffer TJ, Herrmann J, Berliner D et al (2020) Assessment of major mental disorders in a German peripartum cardiomyopathy cohort. ESC Heart Fail. https://doi.org/10.1002/ehf2.12967CrossRefPubMedPubMedCentral

46.

Pfeffer TJ, Schlothauer S, Pietzsch S et al (2019) Increased cancer prevalence in peripartum cardiomyopathy. Cardiooncology 1(2):196–205. https://doi.org/10.1016/j.jaccao.2019.09.008CrossRefPubMedPubMedCentral

47.

Moulig V, Pfeffer TJ, Ricke-Hoch M et al (2019) Long-term follow-up in peripartum cardiomyopathy patients with contemporary treatment: low mortality, high cardiac recovery, but significant cardiovascular co-morbidities. Eur J Heart Fail 21(12):1534–1542. https://doi.org/10.1002/ejhf.1624CrossRefPubMed

48.

Hilfiker-Kleiner D, Haghikia A, Masuko D et al (2017) Outcome of subsequent pregnancies in patients with a history of peripartum cardiomyopathy. Eur J Heart Fail 19(12):1723–1728. https://doi.org/10.1002/ejhf.808CrossRefPubMed

49.

Hoeper MM, Humbert M, Souza R et al (2016) A global view of pulmonary hypertension. Lancet Respir Med 4(4):306–322. https://doi.org/10.1016/s2213-2600(15)00543-3CrossRefPubMed

50.

Bigna JJ, Noubiap JJ, Nansseu JR, Aminde LN (2017) Prevalence and etiologies of pulmonary hypertension in Africa: a systematic review and meta-analysis. BMC Pulm Med 17(1):183. https://doi.org/10.1186/s12890-017-0549-5CrossRefPubMedPubMedCentral

51.

Prins KW, Thenappan T (2016) World health organization group I pulmonary hypertension: epidemiology and pathophysiology. Cardiol Clin 34(3):363–374. https://doi.org/10.1016/j.ccl.2016.04.001CrossRefPubMedPubMedCentral

52.

Frost AE, Badesch DB, Barst RJ et al (2011) The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US contemporary registries. Chest 139(1):128–137. https://doi.org/10.1378/chest.10-0075CrossRefPubMed

53.

Simonneau G, Montani D, Celermajer DS et al (2019) Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. https://doi.org/10.1183/13993003.01913-2018CrossRefPubMedPubMedCentral

54.

Samillan VJ, Peacock AJ (2014) State of the art: pulmonary hypertension. Breathe 10(3):188–197CrossRef

55.

Sliwa K (2020) Heart failure can affect everyone: the ESC Geoffrey Rose lecture. Eur Heart J 41(12):1298–1306. https://doi.org/10.1093/eurheartj/ehaa084CrossRefPubMed

Titel: Neglected cardiovascular diseases and their significance in the Global North
verfasst von: Charle André Viljoen
Julian Hoevelmann
Elani Muller
Prof. Karen Sliwa
Publikationsdatum: 27.01.2021
Verlag: Springer Medizin
Erschienen in: Herz / Ausgabe 2/2021
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-021-05020-7

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Neglected cardiovascular diseases and their significance in the Global North

Abstract

Neu im Fachgebiet Kardiologie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Update Kardiologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

Gender and career in cardiology—a cross-sectional study

Avoiding implantation of a cardioverter-defibrillator by bridging with wearable defibrillator vest

Herz-Kreislauf-Erkrankungen und COVID-19

Kardiologie: Grenzen überwinden, neue Welten entdecken

Cardiac abnormalities in patients with nonalcoholic fatty liver disease

Relationship between neointimal strut bridge and jailed side-branch ostial area

Neu im Fachgebiet Kardiologie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Update Kardiologie